Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) was down 3.8% on Monday . The stock traded as low as C$1.17 and last traded at C$1.27. Approximately 47,723 shares changed hands during trading, a decline of 27% from the average daily volume of 65,261 shares. The stock had previously closed at C$1.32.
Medicenna Therapeutics Trading Down 3.8 %
The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 2.51. The stock has a market capitalization of C$97.07 million, a PE ratio of -3.34 and a beta of 1.21. The business’s 50-day moving average is C$1.59 and its two-hundred day moving average is C$1.93.
Insider Activity
In related news, Senior Officer David Hyman bought 20,000 shares of the company’s stock in a transaction on Thursday, January 9th. The stock was bought at an average cost of C$1.45 per share, with a total value of C$29,000.00. Insiders own 22.57% of the company’s stock.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Featured Articles
- Five stocks we like better than Medicenna Therapeutics
- How to Plot Fibonacci Price Inflection Levels
- How to Invest in Small Cap Stocks
- Bank Stocks – Best Bank Stocks to Invest In
- These Are the Dividend Stocks Insiders Bought in January
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.